field investigational the good I'd milestone broader very amyloid a in and for to development Tolga, which of of our today and cerebral disease important recap therapeutics start morning, Thanks, RNAi news Alnylam a an therapeutics, for progress is recent of treatment Alzheimer's ALN-APP, everyone. like the with that with angiopathy. and marks RNAi
therapeutics to with clinical the CNS. reported the As RNAi week, announced directed an last we first-ever results
brain same our the cause distinct it's second mutations ALN-APP in leading and findings Human the neurodegeneration. the early-onset and Given amyloid can potential angiopathy parties APP worthwhile not disease CAA. form for can interest Alzheimer's Alzheimer's data of fragments with amyloid precursor vessels program. protein, gene deposit for CAA, and or where as blood in plaque the (ab)X of mutations the in shown form discuss Alzheimer's that and the from hemorrhage. the associated treatment Other APP, amyloid of or in have we're the tissue the I genetics or cerebral study which from plaques duplications a importance in gene the to targets investigating to cause disease is, certain that physicians, in further patients from walls intracerebral positive concerned, fact, within bleeds.
CAA ALN-APP least intense interim cause aggregate brain those all and think results are
distinct So this pathophysiological can parent harmful be protein processes. into one APP
shown as in promise CNS animal intrathecal biodistribution on with In With an which APP neuron, here. after a left with microglia types, siRNA oligodendrocyte, we've great all studies, CNS is single astrocytes. and injection that shown showed the the major cell broad knockdown targeting
a could safe, can regimen in significant These findings, X via at the pharmacologic in testing, mechanism, that greatly no on suppression resulted primates durability the APP knockdown reliable, we ultimate specifically hopefully and intrathecal rat the I aggregate the where them our IND-enabling study. therapeutic we conducted was tissues with high part, sustained exaggerated These downstream nonhuman which reproducible the we Phase where in i.e., after protein ongoing. low, excitement demonstrated expected to dose target CNS in toxicology and right, which the histopathology and disease in but to therefore, we were increased studies reduce the short-term see the profile X APP advancement and, medium that GLP hypothesis, dose appeared still given single thereby clinic. that enabled supportive deposit were RNAi time production and in studies doses and was lowering and the that fragments and safety the support months clinical ALN-APP On primate CNS XX-milligram relative terminated, cause.
To experiment significant and around by nonhuman
as A, onset with studies tolerability GLP I trial disease. is early endpoint The just single is Phase B. study, and a Part ALN-APP. The Phase the part followed by enabled primary in a dose was mentioned. X-part multiple designed by conducted Alzheimer's Part being A safety this The of toxicology study I've dose is ascending I patients of
biomarkers Secondary also of explore A shared of biomarkers, impact we Part Interim to on which exploratory objectives we variety ALN-APP. study continue any of includes and of are showing other is data allow The cohorts ascending will doses. characterizing initial assess progression. as enrolling ALN-APP dose further disease whether a focused on pharmacology us in single the
interim Alzheimer's tolerated all been with adverse dose been in A no Today, events study. this single Part onset of has XX well of ALN-APP I time early parity. X the being patients Phase and moderate in enrolled At mild dropouts, the ongoing in cohorts with look, study disease have or
Neurofilament X placebo. and to CSF chain, which be currently Available similar of neurotoxicity light blood for white protein data elevated neuronal cells and to which marker which early out date, damage are data monitored. available a comparable or from was from also the may placebo. NfL, cohort of X study look to drug-induced NfL, appear is Reassuringly, also in
we've to of of intrathecal in months. tested, the the for sustained and up both as was X-month shown. the XX time are and Now XX% day both single after and at beta. milligrams, dose We respectively, the knockdown ALN-APP APP milligrams doses. data biomarkers dose knockdown At treatment that XX rapid, we XX highest at available milligrams, results greater -- To saw all XX both beta, XX% and point for unlike let's available are X and alpha alpha resulted placebo, observed maximum and look biomarkers APP the Excitingly, to as milligrams, rapid than observed sAPP pharmacodynamic date, median early APP reductions engagement X for XX%, to sustained and levels, least dose-dependent all in XX studied knockdown of CSF. soluble target data
milligrams to dose XX to XXX milligrams. Initially, per we intended protocol, from escalate
that to the substantially XX biomarker at knockdown, initial XX% observed of we knockdown our de-escalate given to However, exceeded milligrams milligrams. chose target XX
for knockdown can and appears more and XX we milligram equally APP to with beta. data set, see have limited it promising at similar you while XX both dose milligrams, alpha As substantial the
Accordingly, long what nonhuman in saw overall that where Now This months human well we in available see in notably, we A is for gave CNS anticipate doses quarterly how on Part this longer forward based humans important seeing beyond studies we translation profound effect look believe follow-up. the durable target our we Indeed, study, the X the knockdown drug dosed months We knockdown be beyond. is our and the here I reflects suggest the single to responses the U.K. platform believe for animal in will for of be potential at data in most single with to similar we extending dosing. we data dates or able study to United the suggests Netherlands, less these and continue. suppression. potential Indeed, every X we sustained, effect durability ALN-APP of Phase as the this it infrequent and continued in will X dose see humans, ongoing ascending primate treatment is or dose that's the see portion durability months of as Canada, assays frequently.
Enrollment as the in States. the that
A effect us PD single-dose longer and -- explore to allow and Additional safety. continue will durability enrollment and PK to Part the and long-term in characterize
patients GLP dose include portion Phase doses from be chronic A. we Results I. the conducted GLP at of studies Phase from and knowledge the forward A conducted to will study. support of doses In the Part seen which were multiple of to B parallel B into part study, also we regimens low we've the impressive to will the chronic I and Part Part of study, the of ALN-APP, durability I put without Part A inform These animals in multi-dose toxicology see studies today this knockdown tox and Phase
clinical practice, standard to we regimen that used would frequency be and So any testing. for and exaggerated in dosing doses ultimately relative dose
findings regulatory the be board Specifically, doses, the begin data regulatory authorities. Part in in Netherlands.
In will clinical the study intrathecal the of B the U.K. we medium I for rat chronic Part B we to fact, X has shared partial Canada, studies of to majority on nonhuman month every the the pending The administered due where, the toxicology currently been date and other and for with received hold the have U.S., have low, patients X monthly in in already in in -- primate. Phase from months The approval Part observed A months placed to approval the and FDA enrolled chronic studies. high and multidose is
frequent doses, studies. high Of we administration with of it's the given findings course, exposure chronic these observe in achieved would toxicology that we that not unexpected high
However, and by toxicology between to it's volumes relative exposures species CSF humans. important contextualize
primates, to And annualized those would XX- organ we a in given rat respectively, doses in to potential than relative a exposure tox regimen there's way, example, then milligrams a human the XX-fold dosing studies, exposure even all months, top and chronic in same relative the For and potential X exposures annualized nonhuman and clinical And more nonhuman the greater tested XX rat every greater greater tenfold annualized in there's dose. primate. at if at the be tox of on scale evaluated doses these studies. chronic based
I to we these data, U.S. data, important clinical context in that I support look the them Part guidance arbiter FDA will Phase to with the we preclinical getting discuss all to initiation of forward provides interim and acknowledge well want B be the them. of further from Accordingly, the nevertheless as ultimate new potential as to to information engage plan which
To this may that discussion, that absolutely the I'm these of disease-causing in find be RNAi to CNS. incredible to ever provide data use close the human about part these evidence able first transcripts we the thrilled
can In ALS address with just nature of we targets knockdown and that of animal not but and platform disorders. for the disease-causing studies, the against modular also and many Alzheimer's, demonstrated hope we've our the already diverse genes, CAA, range other reproducible CNS Huntington's,
presenting at medical ALN-APP Part We of study look Phase an upcoming A forward data congress. interim to these the from I
namely where turn product With X in our candidates, advancing to and we're patisiran, vutrisiran me clinical-stage ALN-TTRscXX. efforts amyloidosis that, let hATTR
around ONPATTRO committed polyneuropathy, approved to the the currently ATTR with hereditary we're treat expanding patients. hereditary the both in and amyloidosis ATTR amyloidosis multiple in world, markets label you for to product's cardiomyopathy As the wild-type treatment is know, of and
hold February, that review with committee details amyloidosis In noted discuss. timing advisory or of filing to patients As a many regarding application.
Currently, demonstrated the This for relative delighted more, ATTR of patisiran the learn cardiomyopathy the they've letter, status specific supplemental FDA due you planning the amyloidosis to on patisiran topics patisiran we announced amyloidosis no by also with file in for will they wish FDA issues. standard we an PDUFA have benefits to we to XX outcome cardiomyopathy. we're of discuss from that that stated meeting study, quality X. and of drug will life wild-type And APOLLO-B When with application, identified of with they're the in has sNDA date to is accepted the review FDA improved is hereditary potential new a us given not further placebo. any the October the patients acceptance cardiomyopathy that based as the with been ATTR extend and in communicate ATTR information the functional approved, If months the this pivotal to course. which allow our
the The favored by encouraging We've is XX-month the May. placebo at end data and various we'll this meeting and XX. progression relative that patisiran an these APOLLO-B as from of exploratory of ESC to the FDA profile at sNDA disease have safety on data be presenting results part that of at the morning treatment announced of study supported Heart global the submitted profile been patisiran to Failure month review, biomarkers
on remain track top fully mortality end results XX of events and XX include XXXX. Now all-cause least vutrisiran. This HELIOS-B cardiomyopathy label study with early at ATTR the of committed after point an HELIOS-B, being to up ONPATTRO enrolled, for in treatment growth, in and similar as done wild-type we're and both to we to AMVUTTRA investigational line amyloidosis. also III and Phase assessed expanding which CV the months, is to to hereditary share is of
based with investigational the the therapeutic we a offers potent top entered with IKARIA ALN-TTRscXX is silencing our dosing, profile. on line TTR, in expect Phase the and the in RNAi more an TTRscXX Wrapping durable results and clinic XXXX. for potential potentially transformative for possibility dosing platform annual and and began I late study, TTR up
from year-end that at have to to therapeutic around come.
To programs, treatment late-stage these from investigational the we the patients clinical to disease notable great just as with our a I a in 'XX. offer the zilebesiran, to top ALN-KHK -- which highly and These from and Phase III excited early antihypertensives, highlights type RAAS highlights, years to potential the inhibitors. we NASH. differentiated believe transform addition pipeline treatment been our and mid-stage forward highlight the our of results In of are product mid-XXXX in organic innovation could results hypertension, A and also innovative the by expect we've profile RNAi for we broad of engine the growth our includes top our programs. and with deliver of line for sustainable making with driven wrap believe progress deliver key study representing remain a to look track program dosing ALN-HSD Phase KARDIA-I few milestones where from underlying in KARDIA-II on Alnylam initiated existing oral or initiation Regeneron up of all Phase study including upcoming II we're important We diabetes from line in the of announced and for X driver
review Jeff upcoming Jeff? now and let financials you that, to me it Now to milestones. over with turn our
